Protective dose of a recombinant Newcastle disease LaSota-avian influenza virus H5 vaccine against H5N2 highly pathogenic avian influenza virus and velogenic viscerotropic Newcastle disease virus in broilers with high maternal antibody levels.
The protective dose of a live recombinant LaSota Newcastle disease virus (NDV)-avian influenza H5 vaccine (rNDV-LS/AI-H5) was determined in broiler chickens with high levels of maternal antibodies against NDV and avian influenza virus (AIV). At hatch the geometric mean titers (GMT) of the chickens' maternal antibodies were 2(5.1) and 2(10.3) for NDV and AIV, respectively. At the time of vaccination the GMT was 2(3.1) for NDV and 2(7.9) for AIV. The chickens were vaccinated with one drop (0.03 ml) in the eye at 10 days of age as is typical under field conditions. The test chickens received 10(4.8), 10(5.8), 10(6.8), or 10(7.8) mean chicken embryo infective doses (CEID50) of the rNDV-LS/AI-H5 vaccine. Control chickens were either nonvaccinated, or vaccinated with 10(5.8) or 10(6.8) CEID50 of a commercial live LaSota NDV vaccine. Birds were challenged with either the Mexican highly pathogenic avian influenza virus (HPAIV) strain A/Chicken/Queretaro/14588-19/95 (H5N2) or a Mexican velogenic viscerotropic (VV) NDV strain. One hundred percent of the chickens vaccinated with the rNDV-LS/AI-H5 vaccine were protected against HPAIV and VVNDV when a challenge dose of 10(6.8) EID50 or higher was administered by eye drop. Birds vaccinated with the LaSota NDV vaccine were protected against VVNDV, but not against HPAIV.
Laboratorio Avi-Mex, SA de CV, Bartolache 1862, Colonia del Valle, 01900, México, D. F. México.
David
D
Sarfati-Mizrahi
Bernardo
B
Lozano-Dubernard
Ernesto
E
Soto-Priante
Felipa
F
Castro-Peralta
Ricardo
R
Flores-Castro
Elizabeth
E
Loza-Rubio
Manuel
M
Gay-Gutiérrez
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D002645:Chickens; D005260:Female; D019267:Hemagglutinin Glycoproteins, Influenza Virus / Q000276:immunology*; D007112:Immunity, Maternally-Acquired; D053125:Influenza A Virus, H5N2 Subtype / Q000276:immunology*; D009980:Influenza A virus / Q000276:immunology; D007252:Influenza Vaccines / Q000276:immunology*; D005585:Influenza in Birds / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D008297:Male; D009521:Newcastle Disease / Q000097:blood / Q000276:immunology / Q000517:prevention & control; D009522:Newcastle disease virus / Q000145:classification / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000276:immunology
D000914:Antibodies, Viral; D019267:Hemagglutinin Glycoproteins, Influenza Virus; D007252:Influenza Vaccines; D014614:Vaccines, Synthetic; C109963:hemagglutinin, avian influenza A virus